ZFC3H1: A Potential Drug Target and Biomarker (G196441)

Target Name: ZFC3H1

NCBI ID: G196441

ZFC3H1

ZFC3H1: A Potential Drug Target and Biomarker

Zinc finger chromatin binding proteins (ZFCPs) are a family of non-coding RNAs that play a crucial role in regulating gene expression and DNA replication in various organisms. ZFCPs have been identified as potential drug targets due to their ability to interact with various signaling pathways and their involvement in various cellular processes. One of the ZFCP proteins, ZFC3H1, has been identified as a potential drug target and biomarker. In this article, we will discuss the ZFC3H1 protein, its function, and its potential as a drug target.

Function of ZFC3H1

ZFC3H1 is a 21 kDa protein that is expressed in various tissues, including brain, heart, and testes. It is a zinc finger chromatin binding protein that belongs to the ZFCP family. ZFC3H1 functions as a transcription factor by binding to specific DNA sequences and regulating gene expression.

ZFC3H1 has been shown to play a role in various cellular processes, including cell growth, apoptosis, and transcriptional regulation. It has been shown to promote the expression of neuronal markers, such as NeuN, in the brains of mice and to regulate the expression of genes involved in cell death, such as Bcl-2 in the hearts of mice.

Potential Drug Target

The ZFC3H1 protein has been identified as a potential drug target due to its involvement in various cellular processes that are associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. ZFC3H1 has been shown to promote the growth and survival of cancer cells and has been used as a target for various anti-cancer drugs, including inhibitors of the PI3K/Akt signaling pathway.

In addition, ZFC3H1 has also been shown to be involved in the regulation of neurotransmitter release in the brain and has been linked to various neurological disorders, including Alzheimer's disease and Parkinson's disease. It has been shown to regulate the expression of genes involved in neurotransmitter synthesis, release, and uptake and to play a role in the regulation of neuronal excitability.

Biomarker

ZFC3H1 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. The expression of ZFC3H1 has been shown to be associated with the development and progression of these diseases and has been used as a biomarker for disease diagnosis and monitoring.

For example, ZFC3H1 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease, and has been linked to the expression of genes involved in neurodegeneration. Similarly, ZFC3H1 has also been shown to be involved in the development of cancer and has been linked to the regulation of cell proliferation and apoptosis.

Conclusion

In conclusion, ZFC3H1 is a protein that has been identified as a potential drug target and biomarker due to its involvement in various cellular processes that are associated with various diseases. The expression of ZFC3H1 has been shown to be associated with the development and progression of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Further research is needed to fully understand the role of ZFC3H1 in these diseases and to develop effective therapies that target this protein.

Protein Name: Zinc Finger C3H1-type Containing

Functions: Subunit of the trimeric poly(A) tail exosome targeting (PAXT) complex, a complex that directs a subset of long and polyadenylated poly(A) RNAs for exosomal degradation. The RNA exosome is fundamental for the degradation of RNA in eukaryotic nuclei. Substrate targeting is facilitated by its cofactor MTREX, which links to RNA-binding protein adapters

The "ZFC3H1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZFC3H1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets